A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers

Inclusion Criteria: * Healthy, as judged by the investigator/sub investigator based on the results of physical examination obtained before study drug administration * Body weight: ≥50.0 kg, \<80.0 kg * BMI: ≥17.6, \<26.4 * Serum corrected calcium concentration: ≥9.0mg/dL, \<10.4 mg/dL Exclusion Criteria: * Received any investigational drugs in other clinical or post-marketing studies within 120 days before screening * Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before screening * Received medication (including marketed drug) within 7 days before hospitalization, vitamin preparation including vitamin D and supplement including calcium or is scheduled to receive medication * A deviation from normal criteria range of 12-lead ECG (QT evaluation) * A deviation from the normal range in clinical laboratory tests * Highly sensitive cardiac troponin T (at screening): ≥0.014 ng/mL * History of drug allergies * Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days before admission * Concurrent or previous hepatic disease (e.g., viral hepatitis, drug-induced liver injury) * Concurrent or previous endocrine disorders (e.g.,hyperthyroidism, aberration in growth hormone)